Orforglipron Phase 3: Oral Non-Peptide GLP-1 Drug Achieves 7.9% Weight Loss in Diabetic Obesity
Oral orforglipron 36 mg reduced body weight by 7.9% and HbA1c by 1.4% vs placebo over 40 weeks in obese T2D patients, with 66% achieving ≥5% weight loss in the phase 3 ATTAIN-2 trial.
Quick Facts
What This Study Found
Orforglipron 36 mg: -7.9% body weight, -1.4% HbA1c at 40 weeks; 66% achieved ≥5% weight loss; most common AEs: nausea, diarrhea, vomiting; oral non-peptide GLP-1 RA; phase 3 ATTAIN-2 trial.
Key Numbers
How They Did This
Phase 3, randomized, double-blind, placebo-controlled trial (ATTAIN-2) in 1,439 adults with obesity and T2D, comparing oral orforglipron (multiple doses) to placebo over 40 weeks.
Why This Research Matters
The first non-peptide oral GLP-1 drug achieving meaningful weight loss in a phase 3 trial could make GLP-1 therapy accessible to many more patients who avoid injections.
The Bigger Picture
Orforglipron represents the future of GLP-1 therapy: a daily pill replacing weekly injections, potentially reaching tens of millions more patients.
What This Study Doesn't Tell Us
40-week duration. Weight loss less than injectable semaglutide at comparable timepoints. T2D-specific results; non-diabetic data separate.
Questions This Raises
- ?Will orforglipron achieve injectable-level weight loss with longer treatment?
- ?How does patient preference for oral vs injectable affect real-world adherence?
- ?Will the FDA approve orforglipron based on these results?
Trust & Context
- Key Stat:
- Oral pill, 7.9% weight loss The first non-peptide oral GLP-1 drug achieved meaningful weight loss in a phase 3 trial — a pill instead of an injection
- Evidence Grade:
- Phase 3 RCT — pivotal trial quality. Definitive for approval pathway.
- Study Age:
- Published in 2025, ATTAIN-2 trial.
- Original Title:
- Orforglipron, an oral small-molecule GLP-1 receptor agonist, for the treatment of obesity in people with type 2 diabetes (ATTAIN-2): a phase 3, double-blind, randomised, multicentre, placebo-controlled trial.
- Published In:
- Lancet (London, England), 406(10522), 2927-2944 (2026)
- Authors:
- Horn, Deborah B(3), Ryan, Donna H(2), Kis, Sanja Giljanovic, Alves, Breno, Mu, Yiming, Kim, Sin Gon, Aberle, Jens, Bain, Stephen C, Allen, Sheryl, Sarker, Elizabeth, Wu, Qiwei, Stefanski, Adam, Jouravskaya, Irina
- Database ID:
- RPEP-15308
Evidence Hierarchy
Frequently Asked Questions
Is there a GLP-1 pill that works like Ozempic?
Orforglipron is a daily pill that activates the same GLP-1 receptor as Ozempic but is not a peptide — it's a small molecule. In this phase 3 trial, 36 mg produced 7.9% weight loss and 1.4% HbA1c reduction.
How does the pill compare to injections?
Weight loss (7.9% at 40 weeks) is somewhat less than injectable semaglutide, but the convenience of a daily pill could improve adherence. Longer treatment may produce greater weight loss.
Read More on RethinkPeptides
Related articles coming soon.
Cite This Study
https://rethinkpeptides.com/research/RPEP-15308APA
Horn, Deborah B; Ryan, Donna H; Kis, Sanja Giljanovic; Alves, Breno; Mu, Yiming; Kim, Sin Gon; Aberle, Jens; Bain, Stephen C; Allen, Sheryl; Sarker, Elizabeth; Wu, Qiwei; Stefanski, Adam; Jouravskaya, Irina. (2026). Orforglipron, an oral small-molecule GLP-1 receptor agonist, for the treatment of obesity in people with type 2 diabetes (ATTAIN-2): a phase 3, double-blind, randomised, multicentre, placebo-controlled trial.. Lancet (London, England), 406(10522), 2927-2944. https://doi.org/10.1016/S0140-6736(25)02165-8
MLA
Horn, Deborah B, et al. "Orforglipron, an oral small-molecule GLP-1 receptor agonist, for the treatment of obesity in people with type 2 diabetes (ATTAIN-2): a phase 3, double-blind, randomised, multicentre, placebo-controlled trial.." Lancet (London, 2026. https://doi.org/10.1016/S0140-6736(25)02165-8
RethinkPeptides
RethinkPeptides Research Database. "Orforglipron, an oral small-molecule GLP-1 receptor agonist,..." RPEP-15308. Retrieved from https://rethinkpeptides.com/research/horn-2026-orforglipron-an-oral-smallmolecule
Access the Original Study
Study data sourced from PubMed, a service of the U.S. National Library of Medicine, National Institutes of Health.
This study breakdown was produced by the RethinkPeptides research team. We analyze and report published research findings without making health recommendations. All interpretations are based solely on the published abstract and study data.